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I N HAMSTERS AFTER I N A C T I V A T I O N W I T H
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Eddy et al.^ have reported that simian virus 40 (SV 40) in rhesus monkey kidney
extracts is responsible for the formation of tumors, when injected into newborn hamsters.
I n a recent report f r o m this laboratory,^ it was shown that SV 40 was inactivated
in vitro with Betaprone ( B P L ) * * as evaluated in fissue culture. However, this did not
prove conclusively that the oncogenic properties of SV 40 were destroyed. I n this
communication data are presented to show that B P L also inactivites the oncogenicity
of SV 40 as evaluated in suckling and adult hamsters.

MATERIALS

Preparation

of Cell

AND METHOD:

Extracts

A l l cell extracts were prepared as described by Eddy et al.'
1. Primary Rhesus Monkey Kidney (Rh-MK): Monkey kidney cell cultures were obtained weekly in quart botdes from Microbiological Associates, Bethesda, Maryland. A n
aliquot of cells and fluid was collected from each week's supply for seven consecutive weeks
and the total amount pooled. A n extract was made of the pool and divided into two portions.
One was treated with BPL plus ultraviolet (U.V.) irradiation and the other remained untreated.
2. Primary Human Amnion: The pancreatin procedure'' was used to obtain human
amnion cells which were cuUured for two weeks. The extract from this preparation was not
treated as this material served as a cellular extract control in Experiment No. 1.
Preparation

of Primary

SV 40 Induced

Tumor

for

Transplantation

Tissue from primary tumors were prepared for transplantation by two methods:
1. Minced tissue was cut into minute pieces which could be readily aspirated through a
23 gauge needle.
2. Trypsinized cell suspension (approximately 400,000 cells/ml.) was prepared by standard procedures with 0.25% Difco trypsin (1:250) in Hanks' balanced salt solution free
from Ca and Mg ions. Aliquots from the minced and trypsinized preparations were treated
with 0.35% Betaprone. Untreated aliquots were used as controls.
Betaprone

(BPL)

Solutions

A 10 per cent I(wt/vol) (BPL Sp. Gr. — 1.149)1 BPL solution in cold distilled water
was used. This was made immediately before addition to the materials to be treated and
*Department of Laboratories.
**Betaprone: "Specially purified" grade of beta-propiolactone, available only from Testager & Co.,
Detroit, Michigan.
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added in quantities necessary for the desired concentration. Since BPL hydrolyzes rapidly
in water, all solutions must be freshly prepared in cold distilled water in order to obtain the
maximum amount of the lactone form of the drug."
BPL plus Ultraviolet (U. V.) Irradiation of Monkey Kidney Extract (Experiment
No. 1).
The procedure employed for treating human plasma against the hepatitis virus^'' was used
in these studies. Undiluted monkey kidney extract and BPL in concentration of 0.35 per
cent were made at 4-9° C. by keeping all materials in an ice bath. A l l mixtures were
intermittently and vigorously shaken for 3-5 minutes, then allowed to stand at 4-9° C. for
at least one hour before treatment with U.V. irradiation. A Quartz Oppenheimer chamber
(13 mm wide, 130 mm long and 0.1 mm internal thickness) was used for passage of the
BPL-extract mixture for irradiation. The chamber was placed 1 cm from a G36-T6 ultraviolet sterilamp and the material was passed through the chamber at a flow rate of 1.43 ml.
per minute (approximately 16-20 milliwatts/cmVsec). The mixtures were then incubated
at 37° C. for two hours for rapid action and complete hydrolysis of BPL. Since BPL forms
acid products on hydrolysis, sterile 1 N . NaOH solution was used for p H adjustments
(7.0-7.2) in proportion to the rate of acids formed. This was accomplished by using phenol
red in the tissue culture fluid.
Betaprone
Treatment
of Primary Tumor Tissue Induced
by SV 40
This procedure is the same as that described in the preceding paragraph with the exception
of the U . V. irradiation which was omitted.
Hamsters
Pregnant Syrian Golden hamsters were obtained. 1-2 weeks prior to date of birth
from The Evert Angle Farms, Terre Haute, Indiana. 296 suckling hamsters (1-3 days
old) from 96 mother hamsters were used in Experiment No. 1. A l l injections of cell
extracts were made within a 2-week-period in this experiment. An additional 129 suckling
hamsters (1-2 days old) from 24 mother hamsters were used in Experiment No. 2. In this
experiment tissue transplants were made over a 2-day period. The eleven adult hamsters
used in Experiment No. 2, had been living in the laboratory colony for 7 months prior to use.
PROCEDURES A N D R E S U L T S

The procedure was carried out in two steps. In Experiment N o . 1, the effect
of BPL plus U . V . irradiation on the oncogenic properties of SV 40 was evaluated
in suckling hamsters. In Experiment N o . 2, the effect of BPL treatment in vitro
on the tissues prepared f r o m the primary tumors induced by SV 40 was tested in
suckling and adult hamsters.
Table I
Oncogenicity of SV 40 and Its Inactivation with Betaprone (BPL) Plus Ultraviolet Irradiation
No. of Hamsters
Group

1

Cell Extract
Inocula

W i t h Tumors
Inoculated

5

6

7

8

Without Tumors
Surviving

Dead

51*

52

17

9 months

Rhesus Monkey Kidney
Non-treated

120

11

22

27

42

2

Rhesus Monkey Kidney
BPL plus U V Treated**

91

0

0

0

0

0

71

20

3

Primary Human Amnion
Non-treated

37

0

0

0

0

0

23

14

None
(Control Animals)

48

0

n

0

0

0

32

16

4

* Increasing numbers indicate the accumulative total for the respective month.
**0.35% BPL plus UV irradiation (16-20 mw/cmVsec).
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Table I shows the effect of combined BPL and U.V. irradiation on the oncogenic
properties of SV 40 present in Rh-MK extract. The 296 suckling hamsters were
divided into four groups. In group 1, each of 120 hamsters was inoculated subcutaneously with 0.5 ml. of the non-treated Rh-MK extract containing SV 40, when
1-3 days old. In group 2, each of 91 hamsters was similarly inoculated with an
aliquot of the same extract but treated with 0.35% BPL plus U.V. irradiation. Groups
3 and 4 were used as controls. In group 3, 37 hamsters received extract from
primary human amnion using the same volume, route of injection, and age animals.
In group 4, 48 hamsters received no inoculum. It is readily seen that the only
animals which developed tumors (fibrosarcomas) $ were in group 1; i.e. those receiving
non-treated Rh-MK extract containing SV 40. In this group, eleven tumors had
appeared by the 5th month and by the 9th month a total of 51 animals had developed
tumors. During this period 17 animals died without evidence of tumors and 52 are
still under observation.
In contrast, 91 hamsters in group 2 (BPL plus U.V. treated extract) did not
develop any tumors during the same period of observation. 20 died without evidence
of tumor formation and 71 are still under observation. No tumors occurred among
the control groups 3 and 4. Animals dying during the observation period showed no
evidence of tumor formation. The majority of deaths occurred in the pre-tumor
period, approximately the same number of hamsters dying in each of the four groups.

Table I I
In Vitro Effect of Betaprone on SV 40 Induced Tumor Tissue
No. of Hamsters
Tumor Transplants
( I n Vitro Treatment)

With Tumors
Inoculated

1

2

3

4

Without Tumors
Surviving

Dead

—

0

0

5 weeks

Transplants in Suckling Hamsters (1-2 days old)
(Tissue)

(BPL)
None

Trypsinized*

Minced

14

0

2

14

—

0.35%

23

0

0

0

0

0

22

1

None

49

37

48

—

—

—

0

1

0.35%

43

0

0

0

0

0

41

2

Transplants in Adult Hamsters
(Tissue)
Minced

(BPL)
None

6

0

0

3

4

6

0

0

0.35%

5

0

0

0

0

0

5

0

*The suspension contained approximately 400,000 cells per ml. (Suckling hamsters received 0.5 ml.
and adults received 1.0 ml.).
tThe pathology for these experiments was evaluated by Gerald Fine, M.D., Dept. of Pathology,
Henry Ford Hosp. and will be reported in a separate publication.
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Table I I shows the effect of BPL treatment (in vitro) on tissues prepared from
primary tumors induced by SV 40. The evaluation was made in suckling and adult
hamsters. Tissue transplants in this experiment were made subcutaneously with
0. 5 ml volume in newborn animals (1-2 days old) and 1.0 ml in aduhs. The oncogenic
properties of the primary tumor tissue (whether trypsinized or minced) were effectively
inactivated by 0.35 per cent BPL as evidenced by the lack of growth of the secondary
tumors in suckling hamsters. The suckling hamsters given non-treated transplants
showed 100 per cent tumor formation within 14 to 17 days after transplantation.
The adult hamsters showed the same results, i.e. 100 per cent of the animals which
received the non-treated transplants, developed tumors, whereas no tumors developed
in the animals given the BPL treated transplants.
DISCUSSION

The monkey kidney extract containing the SV 40 was treated with the combined
Betaprone (BPL) and ultraviolet (U.V.) irradiation in the concentrations recommended
for the sterilization of plasma (0.35 per cent BPL plus U.V.).^' This treatment was
used in order to evaluate the effect of the combined treatment on materials used for
inoculation in vivo. This was done because there is concern about the possible
oncongenic properties of BPL." " We believed this fear unwarranted as there is no
BPL present in the biological product afier sterilization. Moreover, in 12 years of
sterilizing biological materials for clinical use'"''"'"'" we have not seen any evidence
of tumor formation attributable to the degradation products of BPL." The experiments
described in this paper substantiate without doubt that BPL destroys the oncogenic
properties of SV 40 as well as inactivates the virus. The fact that Betaprone is
capable of destroying the oncogenic properties of an agent, as well as inactivating the
agent itself, should be convincing reassurance of the lack of oncogenicity of biological
materials sterilized with this compound.
SUMMARY

1. Rhesus monkey kidney extract containing SV 40 was treated with combined Betaprone (BPL) and ultraviolet irradiation. The material, evaluated in suckling'
hamsters, showed 100 per cent destruction of the oncogenic properties of SV 40.
2. Tissue from primary tumors induced by SV 40 was treated with 0.35 per cent
BPL alone and transplanted into suckling and adult hamsters. A l l of the animals
inoculated with non-treated tissue developed tumors whereas none of the animals
inoculated with BPL treated tissue developed tumor growth.
3. These results further substantiate the fact that B'jtaprone treated material is not
oncogenic.
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